Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

181. Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial in hibernation, ready for rapid activation

Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial in hibernation, ready for rapid activation Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial in hibernation, ready for rapid activation Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial (...) . Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial in hibernation, ready for rapid activation. Health Technology Assessment 2015; 19(16) Authors' objectives To (1) evaluate whether or not low-dose corticosteroids given as an adjunct to standard treatment is beneficial in patients who are hospitalised with severe pandemic influenza and (2) develop an 'off-the-shelf' clinical trial that is ready to be activated

2015 Health Technology Assessment (HTA) Database.

182. Planning for a cohort study to investigate the impact and management of influenza in pregnancy in a future pandemic

Planning for a cohort study to investigate the impact and management of influenza in pregnancy in a future pandemic Planning for a cohort study to investigate the impact and management of influenza in pregnancy in a future pandemic Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find

Full Text available with Trip Pro

2015 NIHR HTA programme

183. Homeopathic Oscillococcinum® for preventing and treating influenza and influenza-like illness. (PubMed)

Homeopathic Oscillococcinum® for preventing and treating influenza and influenza-like illness. Influenza is a highly infectious viral disease that is particularly common in the winter months. Oscillococcinum® is a patented homeopathic medicine that is made from a 1% solution of wild duck heart and liver extract, which is then serially diluted 200 times with water and alcohol.To determine whether homeopathic Oscillococcinum® is more effective than placebo in the prevention and/or treatment (...) of influenza and influenza-like illness in adults or children.We searched CENTRAL (2014, Issue 8), MEDLINE (1966 to August week 4, 2014), MEDLINE In-Process & Other Non-Indexed Citations (4 September 2014), AMED (2006 to September 2014), Web of Science (1985 to September 2014), LILACS (1985 to September 2014) and EMBASE (1980 to September 2014). We contacted the manufacturers of Oscillococcinum® for information on further trials.Randomised, placebo-controlled trials of Oscillococcinum® in the prevention

Full Text available with Trip Pro

2015 Cochrane

184. Occurrence of cardiovascular events in patients with coronary artery disease receiving the influenza vaccine

Occurrence of cardiovascular events in patients with coronary artery disease receiving the influenza vaccine "Occurrence of cardiovascular events in patients with coronary artery d" by Dilpreet Bal < > > > > > Title Author Date of Graduation Summer 8-8-2015 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Saje Davis-Risen, MS, PA-C Second Advisor Annjanette Sommers, PA-C, MS Rights . Abstract Background: Cardiovascular disease (...) is the leading cause of death worldwide with coronary artery disease (CAD) making up a majority of those deaths. Coronary artery diseases are atherosclerotic or thrombotic in nature leading to a disparity of blood in the coronary arteries and subsequent infarction of heart muscle. Influenza has been established as a pro-inflammatory agent that has been implicated in increased death rates from cardiovascular disease. With the establishment of this causal relationship, several trials were run to assess

2015 Pacific University EBM Capstone Project

185. Use of neuraminidase inhibitors in influenza

Use of neuraminidase inhibitors in influenza Improving School Governance | 1 Use of neuraminidase inhibitors in influenza Image: Swine Flu virus Sculpture Luke Jerram/Wellcome Images October 2015 1 Use of Neuraminidase Inhibitors in Influenza Contents 1. Summary Background Commentary on the recent publications Pipeline of new drugs and resistance Research priorities Preparedness 3 2. Introduction Terms of reference and conduct of this review Current influenza guidelines 6 3. Studies considered (...) in this report 10 4. Strengths and limitations of the studies considered Quality of evidence Individual patient data and study level analyses Lack of completeness of data Conflicts of interest and transparency 13 5. Synthesis of evidence and implications a) Treatment for any previously healthy people with influenza that is not (currently) severe (‘treat all’ approach) b) Treatment for previously healthy people who develop severe influenza c) Commencing treatment in severely ill individuals more than 48 hours

2015 Academy of Medical Sciences

186. Systematic review with meta analysis: Zanamivir for influenza in adults and children shows limited benefit for treatment of symptomatic influenza and no effect on relevant complications

Systematic review with meta analysis: Zanamivir for influenza in adults and children shows limited benefit for treatment of symptomatic influenza and no effect on relevant complications Zanamivir for influenza in adults and children shows limited benefit for treatment of symptomatic influenza and no effect on relevant complications | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your (...) browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Zanamivir for influenza in adults and children shows

Full Text available with Trip Pro

2015 Evidence-Based Medicine (Requires free registration)

187. Systematic review of the cost-effectiveness of influenza immunization programs: a Canadian perspective

Systematic review of the cost-effectiveness of influenza immunization programs: a Canadian perspective Systematic review of the cost-effectiveness of influenza immunization programs: a Canadian perspective Systematic review of the cost-effectiveness of influenza immunization programs: a Canadian perspective Ting E, Ungar WJ Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Ting E, Ungar WJ. Systematic review of the cost-effectiveness of influenza immunization programs: a Canadian perspective. Toronto, ON: Technology Assessment at SickKids (TASK). 2015 Authors' conclusions From the societal perspective and in many cases the health care system perspective as well, seasonal influenza vaccination was generally found to be a cost-effective strategy. Vaccinating all pregnant and postpartum women against seasonal influenza compared

2015 Health Technology Assessment (HTA) Database.

188. Fluenz Tetra - seasonal influenza in children

Fluenz Tetra - seasonal influenza in children FLUENZTETRA SUMMARY CT13920

2015 Haute Autorite de sante

189. Systematic review of the cost-effectiveness of influenza immunization programs: A Canadian perspective

Systematic review of the cost-effectiveness of influenza immunization programs: A Canadian perspective The Hospital for Sick Children Technology Assessment at SickKids (TASK) FULL REPORT SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF INFLUENZA IMMUNIZATION PROGRAMS: A CANADIAN PERSPECTIVE Author: Eon Ting, BSc, MBA, MSc Supervisor and Senior Responsible Author: Wendy J. Ungar, MSc, PhD Child Health Evaluative Sciences, The Hospital for Sick Children Corresponding Author: Wendy J. Ungar, MSc (...) are the views of the authors and do not necessarily reflect those of The Hospital for Sick Children, Public Health Ontario, or the province of Ontario. CONFLICTS OF INTEREST During the timing of writing this technical report, ET was an employee of AstraZeneca Canada. ii Abstract In Canada, currently no national seasonal influenza immunization program exists. To better inform policy, the cost-effectiveness of influenza immunization programs was examined. Using a best-evidence synthesis approach, 31 economic

2015 SickKids Reports

190. The PAndemic INfluenza Triage in the Emergency Department (PAINTED) pilot cohort study

The PAndemic INfluenza Triage in the Emergency Department (PAINTED) pilot cohort study The PAndemic INfluenza Triage in the Emergency Department (PAINTED) pilot study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit

2015 NIHR HTA programme

191. The design of a survey questionnaire to measure perceptions and behaviour during an influenza pandemic: the Flu TElephone Survey Template (FluTEST)

The design of a survey questionnaire to measure perceptions and behaviour during an influenza pandemic: the Flu TElephone Survey Template (FluTEST) The design of a survey questionnaire to measure perceptions and behaviour during an influenza pandemic: the Flu TElephone Survey Template (FluTEST). The design of a survey questionnaire to measure perceptions and behaviour during an influenza pandemic: the Flu TElephone Survey Template (FluTEST). Rubin GJ, Bakhshi S, Amlôt R, Fear N, Potts HWW (...) , Michie S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Rubin GJ, Bakhshi S, Amlôt R, Fear N, Potts HWW, Michie S. The design of a survey questionnaire to measure perceptions and behaviour during an influenza pandemic: the Flu TElephone Survey Template (FluTEST). Health Services and Delivery Research 2014; 2(41) Authors' objectives During

2014 Health Technology Assessment (HTA) Database.

192. No evidence for benefits of influenza vaccine in institutional healthcare workers

No evidence for benefits of influenza vaccine in institutional healthcare workers No evidence for benefits of influenza vaccine in institutional healthcare workers | Cochrane Primary Care Trusted evidence. Informed decisions. Better health. Enter terms No evidence for benefits of influenza vaccine in institutional healthcare workers Cochrane Trusted evidence. Informed decisions. Better health. Copyright © 2019 The Cochrane Collaboration | | We use cookies to improve your experience on our site.

2014 Cochrane PEARLS

193. Amantadine and rimantadine for influenza A in children and the elderly. (PubMed)

Amantadine and rimantadine for influenza A in children and the elderly. Influenza is an acute respiratory illness caused by influenza A and B viruses. Complications may occur, especially among children and the elderly.To assess the effectiveness and safety of amantadine and rimantadine in preventing, treating and shortening the duration of influenza A in children and the elderly.We searched CENTRAL (2014, Issue 9), MEDLINE (1966 to September week 4, 2014) and EMBASE (1980 to October 2014 (...) ).Randomised controlled trials (RCTs) or quasi-RCTs comparing amantadine and/or rimantadine with no intervention, placebo, other antivirals or different doses or schedules of amantadine or rimantadine in children and the elderly with influenza A.Two review authors independently assessed the search results. We extracted and analysed data using the standard Cochrane methodology.We identified 12 studies (2494 participants: 1586 children and 908 elderly) comparing amantadine and rimantadine with placebo

2014 Cochrane

194. The benefits of influenza vaccine in pregnancy for the fetus and the infant younger than six months of age

The benefits of influenza vaccine in pregnancy for the fetus and the infant younger than six months of age Influenza is a serious problem for infants <6 months of age, whose hospitalization rates for influenza and associated illness are comparable with rates in the elderly. Because influenza vaccines are not effective in this age group, the optimal evidence-based strategy is to administer trivalent inactivated influenza vaccines during pregnancy. Immunizing with trivalent inactivated (...) influenza vaccines in the second and third trimester is well studied and safe, not only providing protection for the pregnant woman and her infant <6 months of age, but also for the fetus by decreasing the risk for low birth weight. Key Words: ALRI; Cocooning; Influenza; TIV

2014 Canadian Paediatric Society

195. Peramivir for acute uncomplicated influenza in adults

Peramivir for acute uncomplicated influenza in adults Peramivir for acute uncomplicated influenza in adults Peramivir for acute uncomplicated influenza in adults NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Peramivir for acute uncomplicated influenza in adults. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC (...) ). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Cyclopentanes; Guanidines; Influenza, Humans Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Centre, School of Health&Population Sciences, University of Birmingham, Public Health building, Edgbaston, Birmingham, B15 2TT. Tel: +44 121 414 7831 Email: nihrhsc@contacts.bham.ac.uk

2014 Health Technology Assessment (HTA) Database.

196. The design of a survey questionnaire to measure perceptions and behaviour during an influenza pandemic: the Flu TElephone Survey Template (FluTEST)

The design of a survey questionnaire to measure perceptions and behaviour during an influenza pandemic: the Flu TElephone Survey Template (FluTEST) The design of a survey questionnaire to measure perceptions and behaviour during an influenza pandemic: the Flu TElephone Survey Template (FluTEST) Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page

2014 NIHR HTA programme

197. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. (PubMed)

Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. Human infections with avian influenza A/H7N9 have resulted in high morbidity and mortality in China.To compare safety and immunogenicity of different doses of influenza A/Shanghai/2/13 (H7N9) vaccine mixed with or without the MF59 adjuvant.Multicenter, randomized, double-blind, phase 2 trial at 4 US sites enrolled 700 adults aged 19 to 64 years beginning (...) or both 15 µg doses (n = 34 [35%; 95% CI, 25%-45%] vs n = 47 [47%; 95% CI, 37%-58%], respectively; P = .10). Recent receipt of seasonal influenza vaccination and older age were associated with attenuated response. No vaccine-related serious adverse events occurred. Solicited postvaccination symptoms were generally mild with more local symptoms seen in participants who received the adjuvant.Point-of-use mixing and administration of 2 doses of H7N9 vaccine at the lowest tested antigen dose with MF59

Full Text available with Trip Pro

2014 JAMA

198. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. (PubMed)

Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. The need to respond quickly to potential influenza pandemics is important. Immunologic priming (initial presentation of an antigen to allow antibody responses on revaccination) with vaccine directed toward an older avian influenza H5 strain might lead to secondary antibody responses to a single dose of more current H5 avian influenza vaccine.To assess priming with the older avian (...) influenza A/Vietnam/1203/2004(H5N1) (Vietnam) vaccine and to conduct dose-response studies with vaccine directed against the more contemporary H5N1 avian influenza virus, influenza A/Anhui/01/2005 (Anhui).Multicenter US randomized clinical trial beginning in June 2010 with follow-up continuing through October 2011 enrolling 72 healthy adults who were vaccinated 1 year previously with the Vietnam vaccine and 565 vaccine-naive adults.Participants who were previously vaccinated with 90 µg of unadjuvanted

Full Text available with Trip Pro

2014 JAMA

199. Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. (PubMed)

Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Chronic bronchitis and chronic obstructive pulmonary disease (COPD) are serious conditions in which patients are predisposed to viral and bacterial infections resulting in potentially fatal acute exacerbations. COPD is defined as a lung disease characterised by obstruction to lung airflow that interferes with normal breathing. Antibiotic therapy has (...) not been particularly useful in eradicating bacteria such as non-typeable Haemophilus influenzae (NTHi) because they are naturally occurring flora of the upper respiratory tract in many people. However, they can cause opportunistic infection. An oral NTHi vaccine has been developed to protect against recurrent infective acute exacerbations in chronic bronchitis.To assess the effectiveness of an oral, whole-cell, non-typeable H. influenzae (NTHi) vaccine in protecting against recurrent episodes of acute

Full Text available with Trip Pro

2014 Cochrane

200. Interventions to increase influenza vaccination rates of those 60 years and older in the community. (PubMed)

Interventions to increase influenza vaccination rates of those 60 years and older in the community. The effectiveness of interventions to increase the uptake of influenza vaccination in people aged 60 and older is uncertain.To assess access, provider, system and societal interventions to increase the uptake of influenza vaccination in people aged 60 years and older in the community.We searched CENTRAL (2014, Issue 5), MEDLINE (January 1950 to May week 3 2014), EMBASE (1980 to June 2014 (...) ), AgeLine (1978 to 4 June 2014), ERIC (1965 to June 2014) and CINAHL (1982 to June 2014).Randomised controlled trials (RCTs) of interventions to increase influenza vaccination uptake in people aged 60 and older.Two review authors independently assessed study quality and extracted influenza vaccine uptake data.This update identified 13 new RCTs; the review now includes a total of 57 RCTs with 896,531 participants. The trials included community-dwelling seniors in high-income countries. Heterogeneity

Full Text available with Trip Pro

2014 Cochrane